Anti-Human Alpha Defensin-5 (HD5) – Purified in vivo PLATINUM™ Functional Grade

Clone 8C8 is most commonly used in vivo in mice to detect and study human alpha-defensin 5 (HD5), but it is only applicable in mouse models genetically engineered to express the human HD5 peptide, since it does not cross-react with the native mouse homolog.

Key in vivo applications include:

• Detection and localization of human HD5 expression: 8C8 is validated for functional in vivo studies such as immunohistochemistry, functional assays, and Western blotting, but specifically on tissues or cells where the human HD5 peptide is expressed (for example, humanized or transgenic mouse models).
• Investigation of human defensin-related immune responses: These models are used to interrogate the function of human alpha-defensin 5 in vivo within an otherwise murine background, allowing researchers to study its role in innate immunity or intestinal biology.
• Evaluation of therapeutic or physiological effects of HD5: The antibody can help monitor the impact of genetic or pharmacologic interventions on human HD5 function in vivo in such transgenic mice.

Important limitations:

• No cross-reactivity with the mouse HD5 homolog: Thus, the clone is not suitable for wild-type mice, but only for mice engineered to express the human peptide.
• Poor recognition of the mature peptide: Some sources note that clone 8C8 may scarcely recognize the mature form of HD5, which can limit detection depending on the experimental context.

In summary, clone 8C8’s in vivo applications in mice are tightly restricted to humanized mouse models for tracking, quantifying, or manipulating human HD5, especially in the context of gut, immune, or antimicrobial research.

Several antibodies and proteins are commonly discussed in the literature in conjunction with the anti-alpha defensin-5 (HD5) antibody clone 8C8. Notably, 8C8 is a monoclonal antibody specific to human alpha defensin-5 (DEFA5 or HD5), used in research involving mucosal immunity, antimicrobial peptides, and related pathologies. However, it is important to clarify that most references to 8C8 are in the context of its stand-alone use as an anti-HD5 antibody, and not as part of a panel with other defined antibodies in published research.

Commonly Co-Used Antibodies

• Anti-L1 Monoclonal Antibodies: One source indicates that the antibodies most commonly referenced alongside 8C8 in the literature are other anti-L1 monoclonal antibodies, specifically 39D4, M12B9, M2E9, and M7B6. However, these antibodies are not directed against alpha defensin-5 but rather target the vaccinia virus L1 protein. This suggests that the context for co-usage is not HD5 research, but rather vaccinia virus L1 protein research.
• Anti-Defensin Family Antibodies: When 8C8 is used in studies of defensins, other anti-defensin antibodies (e.g., against alpha defensin-6 or beta defensin-1) are sometimes used in parallel for broader defensin profiling, but there is no clear, recurring antibody companion specifically cited in the mainstream HD5 literature.
• Isotype Controls: In experimental protocols employing 8C8 (e.g., flow cytometry, immunohistochemistry), isotype controls are routinely used as negative controls, but these are generic immunoglobulins and not specific to HD5 research.
• Complement Component Antibodies: The search did not yield evidence of commonly co-used antibodies targeting other host defense proteins (e.g., complement components, cytokines) in HD5 studies.

Summary Table

Key Points

• The antibodies 39D4, M12B9, M2E9, and M7B6 are commonly referenced alongside 8C8, but only in the context of vaccinia L1 protein research—not in HD5/alpha defensin-5 studies.
• No specific, commonly recurring antibody is consistently reported in the literature as a companion to 8C8 in HD5 research.
• Other anti-defensin antibodies may be used in multiplex panels, but there is no established standard companion antibody for 8C8 in HD5 studies.
• Isotype controls are always used as negative controls but are not specific partners.

If your interest is in HD5/alpha defensin-5 research specifically, there is no well-documented standard panel of antibodies routinely used together with 8C8 in the literature. The available evidence for co-usage is either unrelated (vaccinia L1 antibodies) or incidental (other defensin antibodies), with no established consensus on a companion antibody for 8C8 in HD5 studies.

There is no direct published scientific literature available in the provided search results that describes "clone 8C8" outside of its use as a monoclonal antibody. Clone 8C8 is primarily cited as a monoclonal antibody against Human Defensin Alpha 5 (DEFA5, HD5), used in immunological assays such as immunohistochemistry, Western blot, ELISA, immunophenotyping, and flow cytometry.

Key Findings Regarding the Use of Clone 8C8

• Monoclonal Antibody Specificity: Clone 8C8 is validated for the detection of Defensin Alpha 5 (HD5), a small antimicrobial peptide involved in innate immunity. It is produced and marketed for research use, indicating its specificity and utility in laboratory assays.
• Application in Research: The antibody is used in a variety of immunological and protein detection techniques, highlighting its role in scientific studies of innate immunity and defensin biology.
• No Direct Therapeutic or Mechanistic Studies: Based on the available results, there are no published studies detailing direct functional or mechanistic roles of clone 8C8 in cellular processes, disease models, or therapeutic applications. Its citations in the literature are primarily as a detection reagent, not as an experimental variable or target of substantive research.
• Potential Use in Assays: The reference to clone 8C8 in assay development (e.g., ruling out cross-reactivity in bead-based assays) further underscores its utility as a tool for specific antigen detection, rather than as a subject of mechanistic investigation.

Summary Table

Conclusion

Clone 8C8 is a well-characterized monoclonal antibody against HD5 (DEFA5), widely used as a detection tool in immunology research. There is no evidence in the provided literature that clone 8C8 itself has been the subject of mechanistic, disease, or therapeutic studies; its scientific citations are limited to its utility as a research reagent. If you need information on the biological or clinical significance of Defensin Alpha 5 (the target of clone 8C8), separate literature on HD5 itself would be required.

Dosing regimens for clone 8C8, an anti-human alpha defensin-5 (HD5) monoclonal antibody used in mouse models, are not explicitly detailed in published protocols across standard sources. However, typical dosing for comparable monoclonal antibodies in vivo in mice generally ranges from 5–300 μg per mouse per injection, with regimens varying from a single dose to multiple weekly doses depending on the application and experimental design.

Key points for clone 8C8 usage:

• Dose range: 5–300 μg per mouse per injection is the general guidance for in vivo functional-grade monoclonal antibodies like clone 8C8.
• Dosing frequency: Regimens can range from a single dose to repeated injections (e.g., weekly or every few days), but the exact schedule is determined by experimental goals and mouse model type.
• Route of administration: While not specified for 8C8 directly, intraperitoneal injection is the most common route for similar monoclonal antibodies in mouse studies.
• Model-specific adjustment: The precise regimen may be tailored depending on the mouse model, the disease or immune mechanism under investigation, and the endpoint measured (e.g., depletion vs. neutralization settings).

Mouse model variation:

• No published data indicates that clone 8C8 requires substantially different dosing regimens across specific mouse models (e.g., C57BL/6, NOD SCID, NSG), beyond adjustments made for body weight, disease context, or pharmacokinetic considerations.
• For other monoclonal antibodies, modifications in dose or frequency can occur in immune-deficient vs. immune-competent models or depending on target tissue or intended depletion vs. blocking function.

Summary table: Typical in vivo monoclonal antibody dosing (including 8C8):

*Route for 8C8 inferred from standard practice.

Conclusion:
Exact dosing regimens of clone 8C8 may be adjusted for specific experimental aims, but standard in vivo dosing principles for monoclonal antibodies (5–300 μg/injection, typically intraperitoneal, with flexible schedules) generally apply across mouse models. Researchers should optimize dosing for their target pathway and mouse strain, guided by pilot studies and published in vivo antibody standards.